Vivoryon Therapeutics N.V.
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
09 mar 2015 - 08:07
Statutory name
Vivoryon Therapeutics N.V.
Title
Probiodrug announces enrolment of first patient in Phase 2 Study of novel Treatment for Alzheimer's disease
Comments
First patient enrolled at leading Alzheimer Center in Amsterdam
HALLE/SAALE, Germany, 09 March 2015 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), announces today that the first patient has been enrolled in the Phase 2a "SAPHIR" clinical study of its lead product PQ912 at the Alzheimer Center, VU Medical Center (VUmc), Amsterdam.
Related downloads
Date last update: 02 April 2026